Skip to main content

Advertisement

Table 2 EGFR, MET, p-MET, HGF protein expression levels and MET gene amplification in the complete series

From: Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer

Expression levels test Group Control group P value
n % n %
EGFR      0.053
 Low 0 0.0 2 8.3  
 Medium 2 6.1 3 12.5  
 High 25 75.7 19 79.2  
 ND 6 18.2    
MET      0.066
 Low 8 24.2 16 66.7  
 Medium 16 48.5 5 20.8  
 High 9 27.3 3 12.5  
p-MET      0.060
 Low 27 81.8 20 83.3  
 Medium 4 12.1 4 16.7  
 High 2 6.1 0 0.0  
MET gene      0.092
 Yes 17 51.5 7 29.2  
 No 16 48.5 17 70.8  
HGF      0.369
 Low 9 27.3 11 45.8  
 Medium 17 51.5 10 41.7  
 High 7 21.2 3 12.5  
  1. Different ranges included those cases with low (0–33 %), medium (34–66 %), or high (67–100 %) IHC expression levels determined as a percentage of the Hscore